Freemont Management S.A. Dexcom Inc Transaction History

Freemont Management S.A.

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	SELL	$114.22 - $140.1 $2.71 Million - $3.32 Million	-23,700 Reduced 23.7%	76,300 $10.6 Million
Q4 2023 Feb 09, 2024	SELL	$75.49 - $124.16 $9.38 Million - $15.4 Million	-124,200 Reduced 55.4%	100,000 $12.4 Million
Q3 2023 Nov 09, 2023	BUY	$86.06 - $137.93 $8.02 Million - $12.9 Million	93,200 Added 71.15%	224,200 $20.9 Million
Q4 2022 Feb 10, 2023	BUY	$84.98 - $122.67 $11.1 Million - $16.1 Million	131,000 New	131,000 $14.8 Million

1,014

351M

5.51M

5.6M

Ticker DXCM
Exchange NASDAQ
Sector Healthcare
Industry Medical Devices
Shares Outstandng 386,257,984
Market Cap $30.9B
Description
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM ...

Get notified when there are updates to the investment portfolio of Freemont Management S.A., based on Form 13F filings with the SEC.

Stay updated on Freemont Management S.A. with notifications on news.